Protagonist Therapeutics, Inc. PTGX
130.95 USD -3.43 (-2.55%)
At closeNov 13, 2026, 4:00 PM EST
130.95 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
130.64 Day range 134.90
79.73 52-week range 158.62
- YTD
- +49.93%
- 1 year
- +57.32%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221 HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $170 to $221.- benzinga.com TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160 TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.
benzinga.com Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.28% on an annualized basis producing an average annual return of 19.88%. Currently, Protagonist…
benzinga.com UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184 UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.
benzinga.com Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190 Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.
benzinga.com Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% on an annualized basis producing an average annual return of 20.58%. Currently, Protagonist…
benzinga.com Protagonist Therapeutics Announces $300M Buyback Plan Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its…
benzinga.com Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180 Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.
benzinga.com Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor…
benzinga.com BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190 BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $178 to $190.
benzinga.com Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.- benzinga.com HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170 HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.
- benzinga.com BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178 BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
benzinga.com Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.- benzinga.com Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170 Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.
- benzinga.com Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173 Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $118 to $173.
benzinga.com This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.- benzinga.com Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186 Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Buy and raises the price target from $110 to $186.
benzinga.com Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153 Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.
benzinga.com Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over…- benzinga.com Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151 Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.
- benzinga.com Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145 Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $121 to $145.
benzinga.com This $300 Million Biotech May Be Deeply Mispriced: Analyst Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.
benzinga.com AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
benzinga.com Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.- benzinga.com Protagonist Therapeutics To Present Four Abstracts On Rusfertide In Polycythemia Vera At 2026 European Hematology Association Congress In Sweden Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology…
benzinga.com Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.- benzinga.com Takeda And Protagonist Say FDA Grants Priority Review For Rusfertide As Potential First-In-Class Therapy For Polycythemia Vera, Backed By Phase 3 VERIFY Data Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily…
- benzinga.com Takeda And Protagonist Therapeutics Submitted New Drug Application To FDA Seeking Approval Of Rusfertide For Polycythemia Vera Under the terms of its January 2024 worldwide license and collaboration agreement with Takeda, the submission of the NDA triggers the start of a 120-day period, after which Protagonist can decide to…
- benzinga.com Reported Saturday, Protagonist Therapeutics And Takeda Highlight VERIFY And THRIVE Data Showing Long-Term Hematocrit Control And Reduced Therapeutic Phlebotomy In PV At ASH 2025 52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.
benzinga.com AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday - benzinga.com Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the…
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 951 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 1214 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 216 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
- benzinga.com The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 Upgrades
- benzinga.com Stocks That Hit 52-Week Highs On Monday Before 10 a.m. ET on Monday, 201 companies set new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Friday On Friday morning, 154 companies achieved new highs for the year.- benzinga.com Stocks That Hit 52-Week Highs On Thursday Thursday's morning session saw 167 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday morning, 54 companies achieved new highs for the year.
- benzinga.com Stocks That Hit 52-Week Highs On Monday This morning 161 companies reached new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday This morning 132 companies reached new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday During the morning session on Monday, 118 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday Monday's morning session saw 49 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday This morning 94 companies set new 52-week highs.